1. Pleiotropic effects of the non-calcium phosphate binder sevelamer
I.G. Nikolov, N. Joki, J. Maizel, B. Lacour, T.B. Drüeke, Z.A. Massy 
Kidney International 
Volume 70, Pages S16-S23 (December 2006)
DOI: /sj.ki
Copyright © 2006 International Society of Nephrology Terms and Conditions

2. Figure 1
Kaplan–Meier estimates for all-cause mortality (upper panel) and CV mortality (lower panel) in hemodialysis patients according to baseline hs-CRP quartile.
(Reproduced with permission from Wanner et al. Kidney Int 2003).
Kidney International  , S16-S23DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

3. Figure 2
Possible causes of inflammatory cascade activation in uremia and dialysis.
(Reproduced with permission from Wanner and Metzger, Nephrol Dial Transplant 2002).
Kidney International  , S16-S23DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

4. Figure 3
Mean change in serum uric acid concentrations over 52 weeks by baseline concentration.
(Reproduced with permission from Garg et al. Arth Rheum 2005).
Kidney International  , S16-S23DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

5. Figure 4
A side-by-side comparison of change in mean trabecular bone attenuation and change in mean coronary artery calcification (Agatston) score in subjects randomized to calcium and sevelamer.
(Reproduced with permission from Raggi et al. J Bone Miner Res 2005).
Kidney International  , S16-S23DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

6. Figure 5 Potential pleiotropic effects of sevelamer in CKD.
Kidney International  , S16-S23DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions